Lifecore Biomedical
LFCR
75 hedge funds and large institutions have $119M invested in Lifecore Biomedical in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 23 closing their positions.
157% more call options, than puts
Call options by funds: $537K | Put options by funds: $209K
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
4% more capital invested
Capital invested by funds: $114M → $119M (+$4.98M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3.95% less ownership
Funds ownership: 70.57% → 66.62% (-4%)
5% less funds holding
Funds holding: 79 → 75 (-4)
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.77M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.51M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.08M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$828K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$623K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSC
Cove Street Capital
El Segundo,
California
|
-$7.59M |
| 2 |
Millennium Management
New York
|
-$1.87M |
| 3 |
Jane Street
New York
|
-$1.64M |
| 4 |
TAM
Tocqueville Asset Management
New York
|
-$1.18M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$884K |
LFCR Hedge Fund Activity: Q2 2024 in Review
75 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2024, worth a combined $119M — up 4.4% from $114M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of LFCR and 19 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 23 added.
The largest buyer was BlackRock, adding an estimated $5.77M. The largest seller was Cove Street Capital, cutting an estimated $7.59M.
- 75 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2024, down from 79 in Q1 2024.
- Funds reported $119M of Lifecore Biomedical stock for Q2 2024, up 4.4% quarter-over-quarter.
- 19 funds opened new Lifecore Biomedical positions in Q2 2024 and 23 closed out, a net change of -4 holders.
- The largest Lifecore Biomedical buyer in Q2 2024 was BlackRock, an estimated $5.77M added.
- The largest Lifecore Biomedical seller in Q2 2024 was Cove Street Capital, an estimated $7.59M sold.
Based on aggregated 13F filings for Q2 2024.